SCHEMBL23795367

SCHEMBL23795367

CC1CN(C(=O)OC(C)(C)C)CCCN1S(=O)(=O)c1cccc2cnccc12

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKD3 O94806 3/20 0.56
PRKCG P05129 3/20 0.56
PRKCB P05771 3/20 0.56
PRKCA P17252 3/20 0.56
PRKCH P24723 3/20 0.56
PRKCI P41743 3/20 0.56
PRKCE Q02156 3/20 0.56
PRKCQ Q04759 3/20 0.56
PRKCZ Q05513 3/20 0.56
PRKCD Q05655 3/20 0.56
PRKD1 Q15139 3/20 0.56
PRKACA P17612 2/20 0.56
PRKACG P22612 2/20 0.56
PRKACB P22694 2/20 0.56
SMN1; SMN2 Q16637 2/20 0.56
CYP3A4 P08684 2/20 0.56
CYP2D6 P10635 2/20 0.56
NFKB1 P19838 2/20 0.56
MEN1 O00255 1/20 0.56
TP53 P04637 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24178114 1.00 PRKD3 (0.56) PRKD3PRKCGPRKCBPRKCAPRKCH
SCHEMBL23810407 0.88 CHRM1 (0.49) PRKD3PRKCGPRKCBPRKCAPRKCH
SCHEMBL23795328 0.88 CHRM1 (0.49) PRKD3PRKCGPRKCBPRKCAPRKCH
SCHEMBL30439234 0.88 CHRM1 (0.49) PRKD3PRKCGPRKCBPRKCAPRKCH
SCHEMBL567750 0.88 GPR119 (0.43) PRKD3PRKCGPRKCBPRKCAPRKCH
SCHEMBL567751 0.88 GPR119 (0.43) PRKD3PRKCGPRKCBPRKCAPRKCH
SCHEMBL566233 0.87 ROCK2 (0.44) PRKD3PRKCGPRKCBPRKCAPRKCH
SCHEMBL566234 0.87 ROCK2 (0.44) PRKD3PRKCGPRKCBPRKCAPRKCH
SCHEMBL567211 0.87 ROCK2 (0.44) PRKD3PRKCGPRKCBPRKCAPRKCH
SCHEMBL567120 0.85 ROCK2 (0.42) PRKD3PRKCGPRKCBPRKCAPRKCH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12264146-B2 Rho kinase inhibitor, method for preparing same and uses thereof BEIJING INCREASE INNOVATIVE DRUG CO., LTD (CN) 2025-04-01 US disclosed
CN-111116555-B Rho kinase inhibitor and preparation method and application thereof 北京盈科瑞创新药物研究有限公司 2023-06-02 CN disclosed
US-20220002265-A1 RHO KINASE INHIBITOR, METHOD FOR PREPARING SAME AND USES THEREOF BEIJING INCREASE INNOVATIVE DRUG CO., LTD (CN) 2022-01-06 US disclosed
US-20220002265-A1 RHO KINASE INHIBITOR, METHOD FOR PREPARING SAME AND USES THEREOF BEIJING INCREASE INNOVATIVE DRUG CO., LTD (CN) 2022-01-06 US disclosed
EP-3878846-A1 RHO KINASE INHIBITOR, METHOD FOR PREPARING SAME AND USES THEREOF Beijing Increase Innovative Drug Co., Ltd. (CN) 2021-09-15 EP disclosed
EP-3878846-A1 RHO KINASE INHIBITOR, METHOD FOR PREPARING SAME AND USES THEREOF Beijing Increase Innovative Drug Co., Ltd. (CN) 2021-09-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220002265-A1 RHO KINASE INHIBITOR, METHOD FOR PREPARING SAME AND USES THEREOF ROCK1, RHOA, ROCK2 PRKD3 399/4885PRKCG 194/4885PRKCB 186/4885
US-12264146-B2 Rho kinase inhibitor, method for preparing same and uses thereof ROCK1, RHOA, ROCK2 PRKD3 399/4885PRKCG 194/4885PRKCB 186/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.